All In Biotech

NDA 020527 · Wyeth Pharms

Prempro

Estrogens, Conjugated, Medroxyprogesterone Acetate · Oral-28 · Estrogen

Last checked: Nov 20, 2026Latest source record: Apr 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Nov 17, 1995

Approved uses

4

Original approval plus efficacy supplements

Registered trials

1,166

241 Phase 3, 150 recruiting

FAERS reports

23,488

19,848 serious, 648 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE DEMENTIA Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1 , 5.3) , and Clinical Studies (14.6 , 14.7) ] . The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) (0.625 mg) combined with medroxyprogesterone acetate (MPA) (2.5 mg), relative to placebo [see Warnings and Precautions (5.1) , and Clinical Studies (14.6) ] . The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study...

What it is approved for

From the label in effect Apr 28, 2026.

PREMPRO/PREMPHASE is an estrogen plus progestin indicated in a woman with a uterus for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Prevention of Postmenopausal Osteoporosis ( 1.3 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause 1.3 Prevention of Postmenopausal Osteoporosis

Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • PREMPRO · ESTROGENS, CONJUGATED 0.625MG; MEDROXYPROGESTERONE ACETATE 5MG · TABLET, ORAL-28 · Prescription
  • PREMPRO · ESTROGENS, CONJUGATED 0.625MG; MEDROXYPROGESTERONE ACETATE 2.5MG · TABLET, ORAL-28 · Prescription
  • PREMPRO · ESTROGENS, CONJUGATED 0.45MG; MEDROXYPROGESTERONE ACETATE 1.5MG · TABLET, ORAL-28 · Prescription
  • PREMPHASE 14/14 · ESTROGENS, CONJUGATED 0.625MG,0.625MG; MEDROXYPROGESTERONE ACETATE N/A,5MG · TABLET, ORAL-28 · Prescription
  • PREMPRO · ESTROGENS, CONJUGATED 0.3MG; MEDROXYPROGESTERONE ACETATE 1.5MG · TABLET, ORAL-28 · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Estrogens" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • breast cancer7,889
  • breast cancer female5,791
  • breast cancer metastatic1,505
  • drug ineffective738
  • cerebrovascular accident502
  • depression478
  • headache426
  • anxiety418
  • nausea414
  • deep vein thrombosis397
  • fatigue395
  • hot flush388

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,602
20051,529
20061,384
2007949
20081,913
20094,410
20105,905
20111,202
2012754
2013487
2014363
2015389
2016399
2017311
2018237
2019322
2020371
2021224
2022259
2023157
2024132
2025119
202668

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prempro (Estrogen,Con/M-Progest Acet)

2024 spending

$37.8M

Beneficiaries

19,265

88,870 claims

Per beneficiary

$1,963

$8.25 per unit

View as table
YearSpending
2020$38,655,663
2021$40,112,549
2022$39,740,685
2023$39,672,699
2024$37,818,858

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,773 on PubMed

Sponsor: Pfizer · Also marketed as Premphase 14/14

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.